Stoehr A - Search Results

1

Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry.

Rau M, Buggisch P, Mauss S, Boeker KHW, Klinker H, Müller T, Stoehr A, Schattenberg JM, Geier A. Rau M, et al. Among authors: stoehr a. PLoS One. 2022 Jun 16;17(6):e0264741. doi: 10.1371/journal.pone.0264741. eCollection 2022. PLoS One. 2022. PMID: 35709466 Free PMC article.

2

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).

Hüppe D, Stoehr A, Buggisch P, Mauss S, Klinker H, Teuber G, Hidde D, Lohmann K, Bondin M, Wedemeyer H. Hüppe D, et al. Among authors: stoehr a. J Viral Hepat. 2021 Oct;28(10):1474-1483. doi: 10.1111/jvh.13586. Epub 2021 Aug 12. J Viral Hepat. 2021. PMID: 34339561

3

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry.

Tacke F, Klinker H, Boeker KHW, Merle U, Link R, Buggisch P, Hüppe D, Cornberg M, Sarrazin C, Wedemeyer H, Berg T, Mauss S; DHC-R. Tacke F, et al. Hepatol Commun. 2022 Sep;6(9):2488-2495. doi: 10.1002/hep4.2015. Epub 2022 Jun 5. Hepatol Commun. 2022. PMID: 35666055 Free PMC article.

4

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.

Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Berg T, et al. Among authors: stoehr a. Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15. Aliment Pharmacol Ther. 2019. PMID: 30874328

5

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.

Wedemeyer H, Erren P, Naumann U, Rieke A, Stoehr A, Zimmermann T, Lohmann K, König B, Mauss S. Wedemeyer H, et al. Among authors: stoehr a. Liver Int. 2021 May;41(5):949-955. doi: 10.1111/liv.14829. Epub 2021 Mar 1. Liver Int. 2021. PMID: 33592123

6

Late presentation of chronic hepatitis C patients in the era of direct-acting antivirals-Data from the German Hepatitis C-Registry.

Bischoff J, Mauss S, Lutz T, Cordes C, Klausen G, Scholten S, Hillenbrand H, Cornberg M, Baumgarten A, Rockstroh JK; German Hepatitis C-Registry. Bischoff J, et al. J Viral Hepat. 2021 Nov;28(11):1660-1664. doi: 10.1111/jvh.13576. Epub 2021 Jul 28. J Viral Hepat. 2021. PMID: 34289197 No abstract available.

7

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R).

Krüger K, Rossol S, Krauth C, Buggisch P, Mauss S, Stoehr A, Klinker H, Böker K, Teuber G, Stahmeyer J. Krüger K, et al. Among authors: stoehr a. Z Gastroenterol. 2023 May;61(5):489-503. doi: 10.1055/a-1852-5713. Epub 2022 Jul 15. Z Gastroenterol. 2023. PMID: 35839795 Free PMC article.

8

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).

Cornberg M, Stoehr A, Naumann U, Teuber G, Klinker H, Lutz T, Möller H, Hidde D, Lohmann K, Simon KG. Cornberg M, et al. Among authors: stoehr a. Viruses. 2022 Jul 14;14(7):1541. doi: 10.3390/v14071541. Viruses. 2022. PMID: 35891520 Free PMC article.

9

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3.

Niederau C, Mauss S, Schober A, Stoehr A, Zimmermann T, Waizmann M, Moog G, Pape S, Weber B, Isernhagen K, Sandow P, Bokemeyer B, Alshuth U, Steffens H, Hüppe D. Niederau C, et al. Among authors: stoehr a. PLoS One. 2014 Sep 19;9(9):e107592. doi: 10.1371/journal.pone.0107592. eCollection 2014. PLoS One. 2014. PMID: 25238535 Free PMC article. Clinical Trial.

10

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.

Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J. Buggisch P, et al. Among authors: stoehr a. PLoS One. 2019 Apr 4;14(4):e0214795. doi: 10.1371/journal.pone.0214795. eCollection 2019. PLoS One. 2019. PMID: 30946776 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

194 results

Search Page

Filters